Comparative Pharmacology
Head-to-head clinical analysis: DIUTENSEN R versus HYDROSERPINE PLUS R H H.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUTENSEN R versus HYDROSERPINE PLUS R H H.
DIUTENSEN-R vs HYDROSERPINE PLUS (R-H-H)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIUTENSEN-R is a combination of reserpine and chlorothiazide. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter (VMAT), leading to reduced sympathetic tone. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting natriuresis and reducing plasma volume.
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines from peripheral sympathetic nerve endings, reducing sympathetic tone. Hydralazine directly relaxes arteriolar smooth muscle, decreasing systemic vascular resistance.
One tablet orally once daily. Each tablet contains 2.5 mg reserpine and 25 mg chlorthalidone.
1 tablet orally twice daily. Each tablet contains hydrochlorothiazide 25 mg, reserpine 0.125 mg, and hydralazine hydrochloride 25 mg.
None Documented
None Documented
Terminal half-life: cryptenamine 9-10 h, methylothiazide 18-24 h, reserpine 50-100 h (prolonged due to enterohepatic recirculation and tissue binding; accumulation occurs with daily dosing)
Hydroflumethiazide: 2-3 h; reserpine: 50-100 h (biphasic); hydralazine: 2-4 h (fast acetylators), 6-8 h (slow acetylators).
Renal: 59% (cryptenamine), 50% (methylothiazide), 7% (reserpine); Biliary/fecal: 21% (cryptenamine), 48% (methylothiazide), 90% (reserpine)
Hydroflumethiazide: renal (50-65% unchanged); reserpine: renal (30%) and fecal (60%) as metabolites; hydralazine: renal (85% as metabolites, 10% unchanged).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination